tradingkey.logo

Toragen- Positive Safety Data From Phase 1 Trial Of Tgn-S11, In Patients With Cancers Associated With Hpv

ReutersApr 15, 2025 1:27 PM

-

  • TORAGEN- POSITIVE SAFETY DATA FROM PHASE 1 TRIAL OF TGN-S11, IN PATIENTS WITH CANCERS ASSOCIATED WITH HPV

  • TORAGEN- EVIDENCE OF ACTIVITY IS IDENTIFIED FOR TGN-S11 AS A MONOTHERAPY AND IN COMBINATION WITH KEYTRUDA

  • TORAGEN- PHASE 1 TRIAL MET BOTH PRIMARY ENDPOINTS OF PROVING SAFETY AND REACHING MAXIMUM TOLERATED DOSE OF TGN-S11

Further company coverage: [ ]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI